Dakota Wealth Management Acquires New Holdings in Biogen Inc. $BIIB

Dakota Wealth Management bought a new stake in Biogen Inc. (NASDAQ:BIIB) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 8,677 shares of the biotechnology company’s stock, valued at approximately $1,215,000.

Several other large investors have also recently bought and sold shares of BIIB. Empowered Funds LLC boosted its holdings in shares of Biogen by 64.9% in the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after acquiring an additional 2,777 shares in the last quarter. Focus Partners Wealth boosted its stake in Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after purchasing an additional 6,436 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in shares of Biogen during the 2nd quarter valued at $216,000. Focus Partners Advisor Solutions LLC raised its stake in shares of Biogen by 19.1% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 6,311 shares of the biotechnology company’s stock worth $793,000 after buying an additional 1,010 shares in the last quarter. Finally, Brighton Jones LLC bought a new stake in shares of Biogen in the 2nd quarter worth $641,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.18% of the stock is currently owned by corporate insiders.

Biogen Price Performance

Shares of BIIB opened at $190.73 on Thursday. The business’s 50-day moving average is $181.28 and its 200-day moving average is $162.65. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The company has a market capitalization of $27.99 billion, a price-to-earnings ratio of 21.65, a P/E/G ratio of 1.55 and a beta of 0.16. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm’s revenue was down 7.2% on a year-over-year basis. During the same period in the previous year, the firm posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities research analysts expect that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on BIIB. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Stifel Nicolaus raised their price objective on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Oppenheimer boosted their target price on shares of Biogen from $205.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, January 30th. Mizuho raised their target price on shares of Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Finally, TD Cowen lifted their price target on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $205.04.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.